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Abstract: Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting
acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence
of a number of side-effects. Thus, new AChE inhibitors are being developed and investigated for
their potential use against this disease. Here, we have explored two alternative approaches to get
access to peripherally-acting AChE inhibitors as new agents against myasthenia gravis, by structural
modification of the brain permeable anti-Alzheimer AChE inhibitors tacrine, 6-chlorotacrine, and
huprine Y. Both quaternization upon methylation of the quinoline nitrogen atom, and tethering of a
triazole ring, with, in some cases, the additional incorporation of a polyphenol-like moiety, result
in more polar compounds with higher inhibitory activity against human AChE (up to 190-fold)
and butyrylcholinesterase (up to 40-fold) than pyridostigmine, the standard drug for symptomatic
treatment of myasthenia gravis. The novel compounds are furthermore devoid of brain permeability,
thereby emerging as interesting leads against myasthenia gravis.
Keywords: acetylcholinesterase inhibitors; butyrylcholinesterase inhibitors; quinolinium compounds;
triazoles; structural biology; copper-catalyzed azide-alkyne cycloaddition; click chemistry
1. Introduction
Myasthenia gravis is an autoimmune disease that is associated with antibodies directed against
nicotinic acetylcholine receptors (AChRs) on the postsynaptic membrane at the neuromuscular junction,
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or against other proteins, such as muscle-specific tyrosine kinase (MuSK), low-density lipoprotein
receptor-related protein 4 (LRP4), and agrin, which are involved in AChR clustering on the postsynaptic
membrane and in structural maintenance of the neuromuscular synapse [1,2]. Antibodies against
AChRs may block these receptors by binding to the acetylcholine-binding site, may reduce the number
of available receptors in the membrane by internalization, and may activate the complement cascade,
leading to destruction of the postsynaptic muscle membrane and, hence, negatively affecting AChR
function [2,3]. Failure of neuromuscular transmission leads to fluctuating skeletal muscle fatigue
and weakness upon repeated contraction, which is the main clinical hallmark of myasthenia gravis.
Weakness affects various muscle groups, such as extraocular muscles, which control eye movements,
bulbar muscles in the mouth and throat, responsible for speech and swallowing, and limb and axial
muscles [1].
The worldwide prevalence of myasthenia gravis has been estimated to be 40–180 per million
people, with 10% being children and adolescents, and an annual incidence of 4–12 per million people,
with little geographical variation [1,2,4]. Even though myasthenia gravis remains a rare disease, its
incidence and prevalence are increasing, particularly in the elderly [5], likely as a result of improved
recognition and diagnosis, due to the widespread availability of autoantibody tests, and of increased
life expectancy [4].
Diagnostic testing and symptomatic treatment of myasthenia gravis are based on restoration of
cholinergic transmission at the neuromuscular junction by means of peripherally-acting inhibitors
of acetylcholinesterase (AChE), the enzyme responsible for the hydrolysis of the neurotransmitter
acetylcholine at the synapse [6]. Inhibition of acetylcholine breakdown renders the neurotransmitter
more available for nicotinic AChR stimulation, which alleviates muscle weakness by improving
neuromuscular transmission [7]. The short-acting AChE inhibitor (AChEI) edrophonium chloride
(Enlon®, Tensilon®, Figure 1) is used for diagnosis of myasthenia gravis, because it leads to dramatic
amelioration of the functioning of a particularly weak muscle group immediately after administration.
Other AChEIs, such as pyridostigmine bromide (Mestinon®), neostigmine bromide (Prostigmin®),
and ambenonium dichloride (Mytelase®) (Figure 1), which were introduced in the early 1950s, are used
for the symptomatic treatment of early and mild myasthenia gravis [3,7,8]. Patients who do not
appropriately respond to symptomatic treatment should be treated with immunosuppressive drugs,
which target the underlying pathological immune response, with azathioprine being one of those most
widely used [1,2].
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Figure 1. Chemical structures of peripherally-acting AChEIs used for diagnosis and symptomatic
treatment of myasthenia gravis.
Commercially available AChEIs often permit patients suffering from myasthenia gravis to function
normally, without the need for immunosuppressive drugs. However, their use is accompanied by a
number of muscarinic receptor-mediated side-effects, including abdominal cramps, diarrhea, increased
gastric and bronchial secretions, salivation, lacrimation, nasal discharge, sweating, increased urination,
and bradycardia, which can result in discontinuation of the treatment [7]. Thus, novel AChE inhibitors
with more favorable efficacy/safety profiles are being developed for the symptomatic treatment of
myasthenia gravis.
To ensure a peripheral effect and prevent blood-brain barrier (BBB) crossing and, hence,
potential central cholinergic side-effects, the design of novel AChEIs against myasthenia gravis is
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commonly based on the introduction of permanently charged quaternary nitrogens [9]. A number of
alkylammonium [10], piperidinium [11,12], pyridinium [13], quinolinium [14], and isoquinolinium [15]
derivatives have been developed as potential drug candidates against myasthenia gravis or as reversal
agents of neuromuscular blockade in surgical anesthesia. These compounds usually exhibit AChE
inhibitory potencies in the low micromolar to low nanomolar range. It is noteworthy that some of
these compounds are formally derived, by quaternization, from centrally-acting AChE inhibitors
that are being used for treatment of Alzheimer’s disease, such as donepezil [11,12]. Permanently
charged derivatives of the anti-Alzheimer drug galantamine have been also reported as potent
peripherally-acting AChEIs [16].
Tacrine (1, Scheme 1) was the first AChEI to be approved for treatment of Alzheimer’s disease [17].
Its chlorosubstituted derivatives 6-chlorotacrine, 2 [18], and huprine Y, 3 [19–21], are very potent
AChEIs that were also developed as candidate drugs against Alzheimer’s disease.
In this study, we explored two different approaches to accessing more polar derivatives of
tacrine, 6-chlorotacrine, and huprine Y, which may serve as new peripherally-acting AChEIs of
potential value for treatment of myasthenia gravis. First, we envisaged the classic approach, involving
design of permanently charged quinolinium salts (compounds 4–6, Scheme 1). As an alternative
approach, we also explored the introduction of non-charged polar moieties attached to a tacrine or
6-chlorotacrine core. To this end, we considered the introduction of a 1,2,3-triazole ring (compounds 9
and 10, Scheme 2). The 1,2,3-triazole ring can be readily installed through the prototypic click reaction,
the Huisgen 1,3-dipolar cycloaddition reaction of alkynes and azides [22]. It is a very stable moiety,
non-hydrolytically cleavable, essentially non-oxidizable and non-reducible, with a very large dipole
moment, and with two out of its three nitrogen atoms able to act as weak hydrogen bond acceptors,
so that they can be involved in interactions with biological targets [23]. Indeed, previous studies
have highlighted additional favorable interactions of the 1,2,3-triazole group with residues in the
AChE active-site gorge, when attached to a tacrine moiety by a two-carbon linker. These additional
interactions seem to account for the efficacy of the in situ click chemistry approach (KTGS, kinetic
target-guided synthesis) for the synthesis of dual binding-site AChE inhibitors [24–27]. In addition,
in some target compounds we decided to introduce a second polar moiety, namely a polyphenol-like
moiety at the end of a triazole-containing tether chain (compounds 15 and 16, Scheme 2), with the
double purpose of increasing polarity and producing dual site binding to AChE, i.e., simultaneous
interaction with both the catalytic anionic site (CAS), at the bottom of the active-site gorge, and with
the peripheral anionic site (PAS), at the mouth of the gorge [28], which should result in increased
inhibitory potency.
Here we report the synthesis of the above-mentioned novel polar derivatives of tacrine,
6-chlorotacrine, and huprine Y, and the in vitro evaluation of their inhibitory activities against human
AChE (hAChE) and human butyrylcholinesterase (hBChE), a second human cholinesterase that
hydrolyzes acetylcholine in the blood and in the central nervous system. To assess the peripheral
distribution and discard potential central cholinergic effects of these lead compounds, their brain
permeability was also assessed in vitro. Furthermore, the three-dimensional structures of complexes
of several of these compounds with Torpedo californica AChE (TcAChE) were also solved, in order to
shed light on their mechanism of action.
2. Results and Discussion
2.1. Synthesis of the Target Compounds
The new quinolinium iodide derivatives 4–6 were prepared in good yield by reaction of tacrine,
6-chlorotacrine, and huprine Y, respectively, with excess iodomethane in refluxing methyl ethyl
ketone [29] (Scheme 1).
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77% yield (6).
The synthesis of the triazole-based compounds 9, 10, 15, and 16 started from the known
azidoalkyltacrines 7 [30] and 8 [31], which, in turn, were readily prepared by reaction of
9-chloro-1,2,3,4-tetrahydr acridine or 6,9-dichloro-1,2,3,4-t trahydroacridin with 2-ami oethanol,
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Scheme 2. Synthesis of tacrine-based triazole derivatives 9, 10, 15, and 16. Reagents and conditions:
(i) alkyne (3-butyn-1-ol or 12), CuI, acetonitrile, r.t., 16 h, 63% yield (9), 81% yield (10), 99% yield (13),
60% yield (14); (ii) 3-butynoic acid, EDC·HCl, CH2Cl2, r.t., 2 h, 36% yield; (iii) CSA, MeOH, r.t., 18 h
(for 15, 15% yield) or TBAF, THF, 0 ◦C, 1 h, then r.t., 1 h (for 16, 69% yield).
For the synthesis of the target triazole-based compounds 15 and 16, the new alkyne 12 was
first prepared by amide coupling of the know amine 11 [33] with 3-butynoic acid (Scheme 2).
Copper(I)-catalyzed Huisgen reaction of alkyne 12 with azides 7 and 8 afforded in good yields the
O-TBDMS-pr t cted triazole intermedi tes 3 and 14, which were finally converted into the target
triazole-containing tacr nes 15 and 16 up deprotection with campho sulfonic acid (CSA) in MeOH
or with tetrabutylammonium fluoride (TBAF) in THF, respectively (Scheme 2).
2.2. Biological Profiling of the Target Compounds
The inhibitory activities of the novel compounds against human recombinant AChE and human
serum BChE were evaluated using the method by Ellman et al. [34], using as reference compounds
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pyridostigime, the most widely used AChE inhibitor for treatment of myasthenia gravis, and tacrine,
6-chlorotacrine, and huprine Y, the apolar brain-permeable parent compounds.
Interestingly, all the novel compounds exhibited hAChE and hBChE inhibitory potencies in the
low micromolar to submicromolar, or even low nanomolar range, with most being more potent than
or equipotent to pyridostigmine (Table 1).
Table 1. hAChE and hBChE inhibitory activities and PAMPA-BBB permeabilities of the target and
reference compounds.






4 12.0 ± 1.00 2.85 ± 0.19 1.70 ± 1.50 (CNS−)
5 2.45 ± 0.28 22.3 ± 1.50 1.20 ± 0.80 (CNS−)
6 0.06 ± 0.01 3 3.25 ± 0.15 10.90 ± 1.50 (CNS+)
9 1.73 ± 0.12 0.17 ± 0.01 0.03 ± 0.001 (CNS−)
10 0.20 ± 0.01 3.25 ± 0.17 0.02 ± 0.001 (CNS−)
15 0.25 ± 0.01 0.05 ± 0.00 4 0.03 ± 0.001 (CNS−)
16 0.01 ± 0.00 5 0.29 ± 0.01 2.97 ± 0.61 (CNS±)
pyridostigmine 1.38 ± 0.07 2.13 ± 0.20 -
tacrine 0.32 ± 0.01 0.05 ± 0.00 6 -
6-chlorotacrine 0.01 ± 0.00 7 0.50 ± 0.03 19.8 ± 0.4 (CNS+)
huprine Y 8 0.18 ± 0.01 23.8 ± 2.7 (CNS+)
1 IC50 (half maximal inhibitory concentration) towards human recombinant AChE and human serum BChE.
Values are expressed as mean ± standard error of the mean (SEM) of at least three experiments, each
performed in duplicate; 2 Permeability values (Pe) from the PAMPA-BBB assay and prediction of BBB
permeation. Data are the mean of three independent experiments ± SD. High BBB permeation (CNS+) is
expected for compounds with Pe > 5.19, whereas low BBB permeation (CNS−) is expected for compounds
with Pe < 2.07; 3 IC50 hAChE = 59.2 nM (±5.7); 4 IC50 hBChE = 54.8 nM (±1.6); 5 IC50 hAChE = 7.18 nM (±0.29);
6 IC50 hBChE = 45.8 nM (±3.0); 7 IC50 hAChE = 14.5 nM (±0.9); 8 IC50 hAChE = 1.07 nM (±0.05).
On the basis of the results obtained, some structure-activity relationships (SAR) can be derived:
(i) quaternization of the potent inhibitors tacrine, 6-chlorotacrine, and huprine Y to the quinolinium
derivatives 4–6 results in a drop in their inhibitory potency towards both hAChE and hBChE; (ii) the
ranking of potencies for the quinolinium derivatives remains the same as that found for the noncharged
parent compounds, i.e., huprine derivative 6 > 6-chlorotacrine derivative 5 > tacrine derivative 4 for
hAChE inhibition and tacrine derivative 4 > huprine derivative 6 > 6-chlorotacrine derivative 5,
for hBChE inhibition, with the well-known contribution of the chlorine atom on the benzene ring
of tacrine and huprine derivatives, which is positive for hAChE inhibition [35], and detrimental
for hBChE inhibition [36,37], being retained in the quinolinium derivatives; (iii) introduction of the
triazole-containing side chain at position 9 of tacrine and 6-chlorotacrine results in a slight drop in
inhibitory activity towards both hAChE and hBChE for compounds 9 and 10; (iv) however, when
the triazole-containing side chain is terminated with a polyphenol-like aromatic ring, the resulting
compounds, 15 and 16, are slightly more potent hAChE and hBChE inhibitors than the parent tacrine
and 6-chlorotacrine, likely as a result of multi-site binding within both these cholinesterases; (v) the
positive and negative effects of the chlorine atom in the tacrine derivatives on hAChE and hBChE
inhibitory activities, respectively, also operates in the triazole series.
Inhibition of AChE at the neuromuscular junction results in an extended lifetime of the
neurotransmitter ACh in the synaptic cleft, which repetitively activates the nicotinic AChRs that,
in myasthenia gravis, are affected by autoantibodies. This compensates for the reduction in nicotinic
AChR density, thereby rescuing muscle function. Conversely, inhibition of BChE, which is localized on
the surface of terminal Schwann cells, key components of the neuromuscular junction, not only does not
have an effect on synaptic ACh lifetime, but depresses ACh release into the synaptic cleft, via activation
of α7 nicotinic AChRs, which co-localize with BChE on terminal Schwann cells [38,39]. Thus, selective
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inhibitors of AChE are the preferred option for the functional improvement of muscle function in
myasthenia gravis, as compared to non-selective inhibitors, for which concomitant inhibition of BChE
counteracts the positive effect produced by AChE inhibition. In this context, the huprine and triazole
derivatives 6, 10 and 16 are those with the most potent and selective hAChE inhibitory activity, with
IC50 values of 59.2 nM, 200 nM and 7.18 nM, respectively, and selectivities for hAChE over hBChE
inhibition of 55, 16, and 40, respectively. Most important, these compounds are 23-, 7- and 192-fold
more potent and 37-, 11- and 27-fold more selective hAChE inhibitors than pyridostigmine, the most
widely used drug for treatment of myasthenia gravis and other myasthenic syndromes [40].
To assess whether the two strategies to increase polarity that were used in the design of the
target compounds could produce the expected selective peripheral distribution, preventing entry
into the central nervous system, we evaluated the brain permeability of these compounds by the
widely used in vitro parallel artificial membrane permeability assay for BBB (PAMPA-BBB) [41], using
a lipid extract of porcine brain membrane. As expected, the experimentally determined permeability
values (Pe) of the new polar tacrine and huprine derivatives were, in most cases, in the desired
range of low BBB penetration. The sole exception was the huprine-based quinolinium derivative 6,
which, despite showing a clearly lower Pe value than the parent noncharged compound, huprine Y
(Pe 10.90 vs. 23.8 (10−6 cm/s)), was nevertheless still in the range of high BBB permeation (Table 1, see
also Table 2 for Pe values of commercial drugs uses in assay validation).
Even though most of the novel compounds would be expected to display the desired low brain
penetration, more thorough physicochemical and pharmacokinetic characterization will be necessary
to assess their druglikeness and to address potential ADMET issues, especially in the case of the higher
molecular weight compounds 9, 10, 15, and 16 [42].
2.3. Structural Characterization of Complexes of Compounds 5, 6, and 16 with TcAChE
To obtain insight into the binding mode of the novel quinolinium and triazole derivatives within
the active-site gorge of AChE, these compounds were subjected to co-crystallization trials with TcAChE
and structure determination was attempted for the crystalline complexes thus obtained. Crystals were
soaked for 12 h in mother liquor supplemented with a 1 mM solution of the compound. Only the
co-crystals obtained with compounds 5, 6 and 16 diffracted satisfactorily, thus permitting solution of
their crystal structures. Data collection, structure determination and refinement are further detailed
under Materials and Methods (see also Table 3).
In the crystal structure of TcAChE complexed with the 6-chlorotacrine-based quinolinium
derivative 5, we found three molecules of 5 bound to each of the two monomers present in the
asymmetric unit. In the active site, the binding mode of 5 is different from that of 6-chlorotacrine
in a hybrid derivative described by Nepovimova et al. (pdb code 4TVK) [43]. While the conjugated
system of the molecule is sandwiched between Trp84 and Phe330, making a pi-stacking interaction
with Trp84, the orientation of the chlorine atom is quite unusual. Indeed, several crystal structures
of acetylcholinesterase with 6-chlorotacrine, or even with the closely related compound, huprine X,
the 9-ethyl analog of huprine Y [35], all share a common feature, in which the chlorine atom fits into
a hydrophobic groove contributed by Phe330, Tyr334, Trp432, Met437 and Ile439 (see also, below,
the complex of TcAChE with the 6-chlorotacrine-based triazole derivative 16). In the TcAChE/5
complex, the chlorine atom faces the opposite side of the gorge, pointing towards the main-chain
of residues 116–118 (Figure 2A). To fully validate this new orientation, a Polder map [44], the new
generation of the Phenix omit map, was calculated. This map validated our modeling of 5 within the
active site of TcAChE, with a 13.2 σ electron density peak coinciding with the position of the modeled
chlorine. In this orientation, the nitrogen of the exocyclic amino group H-bonds to the carbonyl of
catalytic His440 (2.73 Å), and the methyl group points towards the entrance of the gorge. The loss of
the important interactions of the chlorine atom in the above-mentioned hydrophobic pocket is most
probably at the origin of the 300-fold drop of potency when compared to 6-chlorotacrine.
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Figure 2. Binding mode of 5 within the TcAChE active site (A,B), and at the PAS (C,D). In the active site,
the major pose is represented in (A), with the conjugated system of 5 pi-stacked between Phe330 and
Trp84. However, the Cl atom does not point towards Trp432, as usually observed for 6-chlorotacrine
derivatives, and the nitrogen of the exocyclic amino group is H-bonded to the carbonyl group of
catalytic His440. A minor pose has also been modeled, with the Cl atom towards the hydrophobic
pocket. In this orientation, the methyl group makes close contact (2.7 Å) with catalytic His440, and
potentially interacts via a weak H-bond [45]. At the peripheral site, two orientations are also observed,
and were refined with identical occupancies (0.5). Hydrophobic interactions are represented as dashed
gray lines, pi-stacking interactions are in green, and hydrogen bonds are in red.
A c oser nspectio of the Polder map revealed a bump in the density t at was not satisfactorily
modeled with this unique orientation. In the refin ent cy les following the addition of 5 in the
model, this positive density bump was retained in the mFo-DFc maps. This bump would perfectly
fit the position of the Cl atom in the usual orientation of 6-chlorotacrine within the AChE active site.
We decided, therefore, to model a second, minor, orientation in the active site of TcAChE (Figure 2B).
In this orientation, the nitrogen atom of the exocyclic amino group is H-bonded to water molecules,
while the methyl group faces the main chain of catalytic Ser200 (2.74 Å). This close contact of the
methyl group with the protein is probably the reason that this conformation is poorly populated.
Other large electron density blobs in the mFo-DFc maps indicated the presence of a second copy
of 5 at the PAS. 5 was modeled, making a pi–pi stacking with Trp279, but in two alternate conformations,
with the Cl atom pointing either into or out of the gorge (Figure 2C,D). Finally, a third molecule of 5
was modeled sandwiched between the aforementioned 5 molecules at the PAS and a symmetry-related
protein molecule of the crystal (Figure 2C). The presence of this third copy of 5 at the PAS thus appears
to be a consequence of crystal packing interactions (not shown).
In the crystal structure of TcAChE complexed with the 6-chlorotacrine-based triazole derivative 16,
the 6-chlorotacrine moiety binds as previously observed, with the conjugated system pi-stacked to Trp84,
and the Cl atom fitting into the hydrophobic groove comprising Phe330, Tyr334, Trp432, Met437, and
Ile439. Along the linker, the triazole ring is engaged in two perpendicular pi-stacking interactions with
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Tyr334 and Phe300, and in H-bonds with Tyr121 and Asp72. From this point onwards, the observed
conformations of the phenolic moiety of 16 differ in the two TcAChE monomers of the asymmetric
unit. In monomer A (Figure 3A), the phenolic moiety makes a pi-stacking interaction with Trp279 in the
PAS. In monomer B (Figure 3B), the ether oxygen of the phenolic moiety H-bonds to the main carbonyl
of Arg289.
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Figure 3. Binding mode of 16 within the active site of TcAChE in the two copies of the monomer in the
asymmetric unit. The binding of the 6-chlorotacrine moiety and of the linker up to the triazole ring
are similar. The binding of the phenolic moiety differs. In (A), the phenolic moiety is stabilized via
a parallel pi-stacking interaction, and is thus more stable than in monomer B (B), in which only the
ether oxygen atom of the phenolic moiety is H-bonded t the main chain nitrogen atom of Arg289.
Parallel and perpendicular pi-stacking interactions are shown in green and magenta respectively, while
H-bonds are depicted in red.
Finally, the crystal structure of the complex of TcAChE with the huprine-based quinolinium
derivative 6 shows that the modified huprine moiety binds at the bottom of the gorge, in the
choline-binding pocket, via pi-stacking interactions with both Trp84 and Phe330 (Figure 4), similarly
to the parent huprines W, X and Y [35,46,47]. However, to accommodate the additional methyl
group, the huprine plane is slightly shifted away from the catalytic His440, and upwards towards
Phe330. When compared to the previously solved structure of the TcAChE/huprine X complex
(pdb code 1e66) [35], the chlorine atom barely moves (0.3 Å, for an overall RMSD of 0.2 Å for 222
superimposed Ca atoms), but the deviation increases up to 0.7 Å at the other extremity of the huprine
moiety. The extra methyl group constrai s accommodatio of the huprine moiety in the active site,
resulti g in close contact with the carbonyl group of His440 (2.7–2.8 Å) and P e330 (distances of
3.2 and 3.3 Å observed in the pi-stack g in e actions, while the short-range pulsion distance between
two carbon atoms is 3.4 Å). Taken together, these repulsive close contacts, generated by the addition
of the methyl group, could account for the 55-fold reduction in inhibitory potency of 6 relative to the
parent huprine Y.
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Figure 4. Binding of 6 to TcAChE. (A) 2mFO-DFc map, contoured at 1 σ, of 6 within the active site
of TcAChE. Clear electron density is observed for the extra methyl group of 6; (B) 6 is depicted in
space-filling format, and the gorge surface is shown in gray. A close contact is observed with the
carb nyl group of His440 (yell w dashed line). Introduction of the m thyl group also resulted in
reorientation of some atoms of 6 that are in close proximity to Phe330 (red arrows in panel (B)).
3. Materials and Methods
3.1. Chemistry
General Methods
Solvents to be used for syntheses were purified with a dry solvent station MB-SPS-800 (MBraun)
immediately prior to use. All reagents were obtained from commercial suppliers (Sigma Aldrich
(Madrid, Spain; Saint Quentin Fallavier, France), Acros (Belgium), TCI (Japan)) unless otherwise stated,
and used without further purification. The reactions were monitored by thin-layer chromatography
(TLC) using silica gel (60 F254) plates. Compounds were visualized by UV irradiation and/or
spraying with 1% aqueous KMnO4, followed by charring at 150 ◦C. Flash column chromatography was
performed on silica gel 60 (230–400 mesh, 0.040–0.063 mm) and silica gel 200 (0.060–0.200 mm). Melting
points of the new compounds were measured with a MFB 595010M Gallenkamp apparatus. 1H-NMR
(300 or 400 MHz) and 13C-NMR (75 or 101 MHz) spectra were recorded on Bruker 300 (Billerica,
Massachusetts, MA, USA) or Varian Mercury 400 spectrometers (Palo Alto, California, CA, USA) at
the Centres Científics i Tecnològics of the University of Barcelona (CCiTUB) and at the Laboratory
COBRA of the Univ rsity of Rouen; chemical shifts are reported in ppm (δ scale) relative to residual
solvent signals (CD3OD, DMSO-d6 or CDCl3 at 3.31/49.0, 2.50/39.5, or 7.26/77.1 ppm, respec ively, in
the 1H/13C-NMRspectra) nd coupling cons ant ar report d in Hertz (Hz). The syn (anti) notation
of the protons at positio 13 of the huprine derivative 6 mean tha the corre onding pr ton at
position 13 is on the same (different) side of the quinoline moiety with respect to the cyclohexene
ring. ass spectra were recorded using the electrospray ionisation technique (ESI). High-resolution
mass spectra (HRMS) were obtained with Varian MAT 311 or LC/MSD TOF Agilent Technologies
spectrometers, using electrospray analysis. The purity of the novel compounds was determined
by analytical HPLC on an Agilent 1100 Series instrument (method A, (NH4)2HPO4/MeOH pH 7.7,
flow rate 1 mL/min, det. 254 nm) or on a Thermo Scientific Surveyor Plus instrument equipped
with a PDA detector (method B, MeCN/H2O/0.10% TFA, flow rate 1 mL/min, det. 254 and 330
nm). Semi-preparative RP-HPLC was performed on a Thermo Scientific SPECTRASYSTEM liquid
chromatography system (P4000) equipped with a UV-visible 2000 detector (method C, Varian Kromasil
C18 column, 10 µm, 21.2 mm × 250 mm, with MeCN and 0.1% aq. TFA as eluents, 0% MeCN (5 min),
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followed by linear gradients of 0–30% (40 min), 30–40% (50 min), and 40–80% (110 min) MeCN, at a
flow rate of 20.0 mL/min. Elution profiles were monitored at 250 and 340 nm.
9-Amino-1,2,3,4-tetrahydro-10-methylacridin-10-ium iodide (4). A solution of tacrine, 1 (300 mg, 1.51 mmol),
in methyl ethyl ketone (25 mL) was heated to 80 ◦C, and then treated dropwise with iodomethane
(6.67 mL, 15.2 g, 107 mmol). The reaction mixture was stirred under reflux overnight and cooled to
room temperature. The resulting precipitate was collected by filtration under vacuum and was washed
with methyl ethyl ketone (3 × 25 mL). The tacrine-based pyridinium derivative 4 (465 mg, 91% yield)
was thus obtained as a white solid: m.p. > 290 ◦C (dec); IR (ATR) ν 3319, 3185 (N-H st), 1645, 1619, 1592,
1554, 1532 (ar-C-C, ar-C-N st); 1H-NMR (400 MHz, DMSO-d6) δ 1.75–1.90 (complex signal, 4H, 2-H2,
3-H2), 2.58 (m, 2H, 1-H2), 3.09 (m, 2H, 4-H2), 3.99 (s, 3H, 10-CH3), 7.69 (m, 1H, 7-H), 7.97 (m, 1H, 6-H),
8.16 (d, J = 8.8 Hz, 1H, 5-H), 8.42 (br s, 2H, 9-NH2), 8.54 (d, J = 8.0 Hz, 1H, 8-H); 13C-NMR (101 MHz,
DMSO-d6) δ 20.3 (CH2), 21.5 (CH2), 23.9 (CH2) (C1, C2, C3), 29.0 (CH2, C4), 35.9 (CH3, 10-CH3), 110.8
(C, C9a), 115.6 (C, C8a), 118.2 (CH, C5), 123.9 (CH), 125.7 (CH) (C7, C8), 133.6 (CH, C6), 138.8 (C, C10a),
154.1 (C), 154.8 (C) (C4a, C9); HRMS (ESI), calculated for C14H17N2 [M]+ 213.1386, found 213.1339;
HPLC purity 99.5% (tR = 15.0 min, method A).
9-Amino-6-chloro-1,2,3,4-tetrahydro-10-methylacridin-10-ium iodide (5). It was prepared as described for 4.
From 6-chlorotacrine, 2 (300 mg, 1.29 mmol), the 6-chlorotacrine-based pyridinium derivative 5 (442 mg,
91% yield) was obtained as a white solid: m.p. >290 ◦C (dec); IR (ATR) ν 3301, 3187 (N-H st), 1642,
1615, 1588, 1553, 1520 (ar-C-C, ar-C-N st); 1H-NMR (400 MHz, DMSO-d6) δ 1.75–1.90 (complex signal,
4H, 2-H2, 3-H2), 2.55 (t, J = 6.0 Hz, 2H, 1-H2), 3.07 (t, J = 6.0 Hz, 2H, 4-H2), 3.97 (s, 3H, 10-CH3), 7.78
(dd, J = 9.2 Hz, J′ = 2.0 Hz, 1H, 7-H), 8.15 (br s, 1H, 9-NHA), 8.28 (d, J = 2.0 Hz, 1H, 5-H), 8.54 (d,
J = 9.2 Hz, 1H, 8-H), 8.95 (br s, 1H, 9-NHB); 13C-NMR (101 MHz, DMSO-d6) δ 20.2 (CH2), 21.4 (CH2),
23.9 (CH2) (C1, C2, C3), 29.0 (CH2, C4), 36.3 (CH3, 10-CH3), 111.5 (C, C9a), 114.2 (C, C8a), 117.9 (CH,
C5), 126.0 (CH), 126.2 (CH) (C7, C8), 138.7 (C), 139.6 (C) (C6, C10a), 154.6 (C), 154.9 (C) (C4a, C9); HRMS
(ESI), calculated for C14H1635ClN2 [M]+ 247.0997, found 247.0999; HPLC purity 99.7% (tR = 17.7 min,
method A).
12-Amino-3-chloro-6,7,10,11-tetrahydro-5,9-dimethyl-7,11-methanocycloocta[b]quinolin-5-ium iodide (6).
It was prepared as described for 4. From huprine Y, 3 (300 mg, 1.05 mmol), the huprine-based
pyridinium derivative 6 (346 mg, 77% yield) was obtained as a white solid: m.p. 283–285 ◦C (dec);
IR (ATR) ν 3314, 3188 (N-H st), 1649, 1611, 1585, 1522 (ar-C-C, ar-C-N st); 1H-NMR (400 MHz,
DMSO-d6) δ 1.52 (s, 3H, 9-CH3), 1.77 (br d, J = 12.0 Hz, 1H, 13-Hsyn), 1.87 (d, J = 17.6 Hz, 1H, 10-Hendo),
superimposed in part 1.86–1.92 (m, 1H, 13-Hanti), 2.40 (dd, J = 17.6 Hz, J′ = 3.6 Hz, 1H, 10-Hexo), 2.80
(br s, 1H, 7-H), 3.03 (d, J = 18.0 Hz, 1H, 6-Hendo), 3.23 (dd, J = 18.0 Hz, J′ = 6.0 Hz, 1H, 6-Hexo), 3.40
(br s, 1H, 11-H), 3.97 (s, 3H, 5-CH3), 5.50 (br d, J = 5.6 Hz, 1H, 8-H), 7.80 (dd, J = 9.2 Hz, J′ = 2.0 Hz,
1H, 2-H), 8.27 (d, J = 2.0 Hz, 1H, 4-H), 8.36 (br s, 1H, 12-NHA), 8.58 (d, J = 9.2 Hz, 1H, 1-H), 8.94 (br s,
1H, 12-NHB); 13C-NMR (101 MHz, DMSO-d6) δ 23.0 (CH3, 9-CH3), 26.0 (CH), 26.6 (CH) (C7, C11), 26.7
(CH2, C13), 34.7 (CH2), 35.7 (CH2) (C6, C10), 36.4 (CH3, 5-CH3), 114.6 (C), 115.1 (C) (C11a, C12a), 117.8
(CH, C4), 124.2 (CH, C8), 126.1 (CH), 126.2 (CH) (C1, C2), 132.8 (C, C9), 138.6 (C, C3), 139.7 (C, C4a),
153.7 (C), 154.1 (C) (C5a, C12); HRMS (ESI), calculated for C18H2035ClN2 [M]+ 299.1310, found 299.1316;
HPLC purity 99.7% (tR = 22.1 min, method A).
2-{1-[2-(1,2,3,4-Tetrahydroacridin-9-ylamino)ethyl]-1H-1,2,3-triazol-4-yl}ethanol (9). To a solution of azide 7
(50 mg, 187 µmol) in acetonitrile (HPLC grade, conc = 0.06 M), 3-butyn-1-ol (16 mg, 224 µmol) was
added via a syringe. The reaction flask was then protected from light, and CuI (36 mg, 187 µmol) was
introduced. The reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated,
and the crude product was directly purified by column chromatography (silica gel, CH2Cl2/MeOH
mixtures, gradient elution, 100:0 to 95:5, 90:10 and 85:15) to afford the triazole derivative 9 (40 mg, 63%
yield) as an orange-brown oil; Rf (CH2Cl2/MeOH 9:1) 0.53; 1H-NMR (300 MHz, CD3OD) δ 1.89–1.91
(m, 4H, tacrine 2-H2, 3-H2), 2.62 (t, J = 6.0 Hz, 2H, tacrine 1-H2), 2.77 (t, J = 6.9 Hz, 2H, 2-H2), 2.96
Molecules 2018, 23, 634 11 of 19
(t, J = 5.7 Hz, 2H, tacrine 4-H2), 3.60 (t, J = 6.9 Hz, 2H, 1-H2), 4.15 (t, J = 5.4 Hz, 2H, NH-CH2-CH2-N),
4.60 (t, J = 5.4 Hz, 2H, NH-CH2-CH2-N), 7.41 (ddd, J = 7.8 Hz, J′ = 6.9 Hz, J′′ = 1.2 Hz, 1H, tacrine
7-H), 7.58 (s, 1H, triazole 5-H), 7.62 (ddd, J = 8.1 Hz, J′ = 6.9 Hz, J′′ = 1.2 Hz, 1H, tacrine 6-H), 7.75
(d, J = 7.8 Hz, 1H, tacrine 8-H), 7.98 (d, J = 8.1 Hz, 1H, tacrine 5-H); 13C-NMR (75 MHz, CD3OD) δ 22.9
(CH2, tacrine C2), 23.6 (CH2, tacrine C3), 25.7 (CH2, tacrine C1), 29.7 (CH2, C2), 32.6 (CH2, tacrine
C4), 48.8 (CH2, NH-CH2-CH2-N), 51.7 (CH2, NH-CH2-CH2-N), 61.9 (CH2, C1), 116.9 (C, tacrine C9a),
120.1 (C, tacrine C8a), 124.4 (CH, triazole C5), 124.5 (CH, tacrine C5), 125.3 (CH, tacrine C8), 125.8 (CH,
tacrine C7), 131.3 (CH, tacrine C6), 144.7 (C, triazole C4), 146.2 (C, tacrine 10a), 154.2 (C, tacrine C9),
157.1 (C, tacrine C4a); MS (ESI+) 338 [M + H]+; HRMS (ESI+), calculated for C19H24N5O [M + H]+
338.1981, found 338.1978; HPLC purity 99.9% (tR = 17.4 min, method B).
2-{1-[2-(6-Chloro-1,2,3,4-tetrahydroacridin-9-ylamino)ethyl]-1H-1,2,3-triazol-4-yl}ethanol (10). It was
prepared as described for 9. From azide 8 (40 mg, 133 µmol), the triazole derivative 10 (40 mg,
81% yield) was obtained as an orange-brown oil; Rf (CH2Cl2/MeOH 9:1) 0.27; 1H-NMR (300 MHz,
CD3OD) δ 1.89–1.91 (m, 4H, tacrine 2-H2, 3-H2), 2.61 (t, J = 6.0 Hz, 2H, tacrine 1-H2), 2.74 (m, 2H,
2-H2), 2.95 (t, J = 5.7 Hz, 2H, tacrine 4-H2), 3.65 (m, 2H, 1-H2), 4.11 (t, J = 5.7 Hz, 2H, NH-CH2-CH2-N),
4.59 (t, J = 5.7 Hz, 2H, NH-CH2-CH2-N), 7.36 (dd, J = 9.3 Hz, J′ = 2.1 Hz, 1H, tacrine 7-H), 7.57 (s, 1H,
triazole 5-H), 7.75 (d, J = 2.1 Hz, 1H, tacrine 5-H), 7.94 (d, J = 9.3 Hz, 1H, tacrine 8-H); 13C-NMR
(75 MHz, CD3OD) δ 23.0 (CH2, tacrine C2), 23.6 (CH2, tacrine C3), 25.8 (CH2, tacrine C1), 29.7 (CH2,
C2), 33.3 (CH2, tacrine C4), 48.8 (CH2, NH-CH2-CH2-N), 51.7 (CH2, NH-CH2-CH2-N), 61.9 (CH2, C1),
117.7 (C, tacrine C9a), 118.9 (C, triazole C4), 120.7 (C, tacrine C8a), 124.3 (CH, triazole C5), 125.1 (CH,
tacrine C5), 125.9 (CH, tacrine C7), 126.4 (CH, tacrine C8), 136.6 (C, tacrine C6), 146.5 (C, tacrine 10a),
153.4 (C, tacrine C9), 159.2 (C, tacrine C4a); MS (ESI+) 372 [M + H]+; HRMS (ESI+), calculated for
C19H2335ClN5O [M + H]+ 372.1591, found 372.1586; HPLC purity 99.1% (tR = 17.9 min, method B).
N-[4-(tert-Butyldimethylsilyloxy)-3-methoxybenzyl]-3-butynamide (12). To a solution of [4-(tert-
butyldimethylsilyloxy)-3-methoxyphenyl]methanamine, 11 (2.10 g, 7.85 mmol), in dichloromethane
(40 mL), 3-butynoic acid (0.66 g, 7.85 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride, EDC·HCl (1.18 g, 6.16 mmol), were successively added. The reaction mixture
was stirred at room temperature for 2 h, diluted with water, and extracted with dichloromethane
(2 × 100 mL). The combined organic phases were washed with water, then with brine, dried over
anhydrous MgSO4, and concentrated under reduced pressure. The crude product was purified by flash
column chromatography (silica gel, cyclohexane/EtOAc, 80:20 to 70:30) to yield the alkynamide
12 (950 mg, 36% yield) as a yellow-orange solid. The isomerization allene derivative was also
isolated (430 mg, 16% yield) as an off-white solid. 12: 1H-NMR (300 MHz, CDCl3) δ 0.14 [s, 6H,
OSi(CH3)2C(CH3)3], 0.98 [s, 9H, OSi(CH3)2C(CH3)3], 2.33 (t, J = 2.7 Hz, 1H, 4-H), 3.26 (d, J = 2.7 Hz, 2H,
2-H2), 3.79 (s, 3H, 3′-OCH3), 4.39 (d, J = 5.7 Hz, 2H, CONHCH2), 6.67–6.85 (complex signal, 3H, 2′-H,
5′-H, 6′-H); 13C-NMR (75 MHz, CDCl3) δ−4.5 [2CH3, OSi(CH3)2C(CH3)3], 18.6 [C, OSi(CH3)2C(CH3)3],
25.8 [3CH3, OSi(CH3)2C(CH3)3], 27.5 (CH2, C2), 43.9 (CH2, CONHCH2), 55.6 (CH3, 3′-OCH3), 74.4
(CH, C4), 77.5 (C, C3), 111.9 (CH, C2′), 120.2 (CH, C5′), 121.0 (CH, C6′), 131.1 (C, C1′), 144.7 (C, C4′),
151.2 (C, C3′), 166.0 (C, C1); MS (ESI+) 334 [M + H]+.
N-[4-(tert-Butyldimethylsilyloxy)-3-methoxybenzyl]-2-{1-[2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl]-1H-1,
2,3-triazol-4-yl}acetamide (13). It was prepared as described for 9. From azide 7 (40 mg, 150 µmol),
the triazole derivative 13 (89 mg, 99% yield) was obtained as a brown oil; Rf (CH2Cl2/MeOH 9:1)
0.30; 1H-NMR (300 MHz, CD3OD) δ 0.05 [s, 6H, OSi(CH3)2C(CH3)3], 0.90 [s, 9H, OSi(CH3)2C(CH3)3],
1.65–1.95 (complex signal, 4H, tacrine 2-H2, 3-H2), 2.59 (t, J = 6.0 Hz, 2H, tacrine 1-H2), 2.93
(t, J = 6.0 Hz, 2H, tacrine 4-H2), 3.57 (s, 2H, 2-H2), 3.72 (NH), 3.77 (s, 3H, Ph-3-OCH3), 4.06 (t, J = 5.4 Hz,
2H, NH-CH2-CH2-N), 4.24 (s, 2H, CONHCH2), 4.60 (t, J = 5.4 Hz, 2H, NH-CH2-CH2-N), 6.64–6.75
(complex signal, 2H, Ph-5-H, Ph-6-H), 6.82 (s, 1H, Ph-2-H), 7.37 (br t, J = 7.5 Hz, 1H, tacrine 7-H), 7.58
(br t, J = 7.5 Hz, 1H, tacrine 6-H), 7.69 (s, 1H, triazole 5-H), 7.74 (br d, J = 8.4 Hz, 1H, tacrine 8-H), 7.90
(br d, J = 8.5 Hz, 1H, tacrine 5-H); 13C-NMR (75 MHz, CD3OD) δ −3.6 [2CH3, OSi(CH3)2C(CH3)3],
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18.8 [C, OSi(CH3)2C(CH3)3], 23.1 (CH2, tacrine C2), 23.7 (CH2, tacrine C3), 25.8 (CH2, tacrine C1), 26.2
[3CH3, OSi(CH3)2C(CH3)3], 33.1 (CH2, tacrine C4), 33.6 (CH2, C2), 44.2 (CH2, CONHCH2), 48.8 (CH2,
NH-CH2-CH2-N), 51.7 (CH2, NH-CH2-CH2-N), 56.3 (CH3, Ph-3-OCH3), 112.5 (CH, Ph-C2), 116.1 (CH,
Ph-C5), 117.6 (C, tacrine C9a), 120.7 (Ph-C6, tacrine C8a), 124.2 (CH, tacrine C5), 125.4 (CH, triazole
C5), 125.6 (CH, tacrine C7), 126.4 (CH, tacrine C8), 130.7 (CH, tacrine C6), 131.1 (C, Ph-C1), 142.9 (C,
triazole C4), 145.9 (C, Ph-C4), 146.8 (C, tacrine C10a), 148.9 (C, Ph-C3), 153.2 (C, tacrine C9), 158.1 (C,
tacrine C4a), 171.4 (C, C1); MS (ESI+) 601 [M + H]+.
N-[4-(tert-Butyldimethylsilyloxy)-3-methoxybenzyl]-2-{1-[2-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)ethyl]
-1H-1,2,3-triazol-4-yl}acetamide (14). It was prepared as described for 9. From azide 8 (110 mg, 365 µmol),
the triazole derivative 14 (138 mg, 60% yield) was obtained as a brown oil; Rf (cyclohexane/AcOEt 6:4)
0.10; 1H-NMR (300 MHz, DMSO-d6) δ 0.08 [s, 6H, OSi(CH3)2C(CH3)3], 0.93 [s, 9H, OSi(CH3)2C(CH3)3],
1.78 (complex signal, 4H, tacrine 2-H2, 3-H2), 2.59 (t, J = 5.8 Hz, 2H, tacrine 1-H2), 2.88 (br s, 2H, 2-H2), 3.50
(m, 2H, tacrine 4-H2), 3.69 (s, 3H, Ph-3-OCH3), 3.84 (m, 2H, NH-CH2-CH2-N), 4.19 (s, 2H, CONHCH2),
4.54 (m, 2H, NH-CH2-CH2-N), 5.75 (NH-CH2-CH2-N), 6.66 (complex signal, 2H, Ph-5-H, Ph-6-H), 6.85
(s, 1H, Ph-2-H), 7.32 (d, J = 9.0 Hz, 1H, tacrine 7-H), 7.76–8.03 (complex signal, 3H, triazole 5-H, tacrine
5-H and 8-H), 8.49 (CONHCH2); 13C-NMR (75 MHz, DMSO-d6) δ −4.8 [2CH3, OSi(CH3)2C(CH3)3],
18.1 [C, OSi(CH3)2C(CH3)3], 22.0 (CH2, tacrine C2), 22.3 (CH2, tacrine C3), 24.7 (CH2, tacrine C4), 25.5
[3CH3, OSi(CH3)2C(CH3)3], 32.7 (CH2, C2), 33.2 (CH2, tacrine C1), 40.2 (CH2, NH-CH2-CH2-N), 47.6
(CH2, NH-CH2-CH2-N), 49.6 (CH2, CONHCH2), 55.2 (CH3, Ph-3-OCH3), 111.5 (CH, Ph-C2), 117.1
(C, tacrine C9a), 118.7 (C, triazole C4), 119.3 (C, tacrine C8a), 119.4 (CH, Ph-C5), 120.1 (CH, Ph-C6), 123.8
(2CH, tacrine C7, triazole C5), 125.2 (CH, tacrine C8), 126.3 (CH, tacrine C5), 132.7 (C, Ph-C1), 132.9
(C, tacrine C-6), 147.1 (C, Ph-C4), 149.9 (C, tacrine C10a), 150.3 (C, Ph-C3), 152.4 (C, tacrine C9), 159.3
(C, tacrine C4a), 168.8 (C, C1); MS (ESI+) 635 [M]+.
N-[4-(hydroxy)-3-methoxybenzyl]-2-{1-[2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl]-1H-1,2,3-triazol-4-
yl}acetamide (15). Camphorsulfonic acid (34 mg, 146 µmol) was added to a solution of the
TBDMS-protected triazole derivative 13 (89 mg, 148 µmol) in MeOH (5 mL), and the reaction mixture
was stirred at room temperature for 18 h. The solvent was evaporated at reduced pressure, and
the crude product was directly purified by column chromatography (silica gel, AcOEt/MeOH
mixtures, gradient elution, from 100:0 to 90:10, 80:20 and 50:50), to afford impure triazole derivative 15.
After re-purification by RP-HPLC (Kromasil, MeCN/H2O (0.1% TFA), 40 min, gradient method C),
compound 15 (11 mg, 15% yield) was obtained as a light brown solid; Rf (AcOEt/MeOH 1:1) 0.63;
1H-NMR (300 MHz, CD3OD) δ 1.92–2.05 (complex signal, 4H, tacrine 2-H2, 3-H2), 2.62 (m, 2H, tacrine
1-H2), 3.01 (m, 2H, tacrine 4-H2), 3.56 (s, 2H, 2-H2), 3.84 (s, 3H, Ph-3-OCH3), 4.28 (s, 2H, CONHCH2),
4.45 (t, J = 5.7 Hz, 2H, NH-CH2-CH2-N), 4.77 (t, J = 5.7 Hz, 2H, NH-CH2-CH2-N), 6.72 (complex signal,
2H, Ph-5-H, Ph-6-H), 6.85 (s, 1H, Ph-2-H), 7.58 (m, 1H, tacrine 7-H), 7.76–7.89 (complex signal, 3H,
triazole 5-H, tacrine 5-H and 6-H), 8.27 (d, J = 9.0 Hz, 1H, tacrine 8-H); 13C-NMR (75 MHz, DMSO-d6)
δ 21.7 (CH2, tacrine C2), 22.8 (CH2, tacrine C3), 24.9 (CH2, tacrine C4), 29.4 (CH2, tacrine C1), 33.0
(CH2, C2), 44.2 (CH2, CONHCH2), 48.5 (CH2, NH-CH2-CH2-N), 51.1 (CH2, NH-CH2-CH2-N), 56.4
(CH3, Ph-3-OCH3), 112.4 (CH, Ph-C2), 114.4 (C, tacrine C9a), 116.1 (CH, Ph-C5), 117.6 (C, tacrine C8a),
120.2 (CH, tacrine C8), 121.3 (CH, Ph-C6), 125.5 (CH, triazole C5), 125.9 (CH, tacrine C7), 126.9
(2CH, tacrine C5 and C6), 131.1 (C, triazole C4), 134.2 (C, Ph-C1), 139.4 (C, Ph-C4), 146.9 (C, Ph-C3),
149.0 (C, tacrine 10a), 152.7 (C, tacrine C9), 158.8 (C, tacrine C4a), 180.1 (C, C1); MS (ESI+) 487 [M]+;
HRMS (ESI+), calculated for C27H31N6O3 [M + H]+ 487.2458, found 487.2455; HPLC purity 98.8%
(tR = 20.6 min, method B).
2-{1-[2-(6-Chloro-1,2,3,4-tetrahydroacridin-9-ylamino)ethyl]-1H-1,2,3-triazol-4-yl}-N-[4-(hydroxy)-3-
methoxybenzyl]acetamide (16). A solution of the TBDMS-protected triazole derivative 14 (114 mg,
179 µmol) in anhydrous THF (1.8 mL) was cooled to 0 ◦C, and then treated dropwise with TBAF
(0.10 mL, 120 µmol). The reaction mixture was stirred at 0 ◦C for 1 h and at room temperature
for an additional 1 h. To the resulting mixture AcOEt (15 mL) and 10% aqueous Na2CO3 were
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added. The phases were separated, and the aqueous phase was extracted with AcOEt/THF.
The combined organic extracts were dried over anhydrous Na2SO4, and concentrated at reduced
pressure. Purification of the crude product by column chromatography (silica gel, EtOAc/MeOH
mixtures, gradient elution, from 100:0 to 90.10, 80:20, and 50:50) afforded the triazole derivative 16
(64 mg, 69% yield) as a green-brown oil; Rf (AcOEt/MeOH 1:1) 0.63; 1H-NMR (300 MHz, CD3OD)
δ 1.82–1.90 (complex signal, 4H, tacrine 2-H2, 3-H2), 2.55 (m, 2H, tacrine 1-H2), 2.89 (m, 2H, tacrine
4-H2), 3.58 (s, 2H, 2-H2), 3.77 (s, 3H, Ph-3-OCH3), 4.06 (t, J = 5.4 Hz, 2H, NH-CH2-CH2-N), 4.24 (s, 2H,
CONHCH2), 4.59 (t, J = 5.4 Hz, 2H, NH-CH2-CH2-N), 6.68 (complex signal, 2H, Ph-5-H, Ph-6-H), 6.81
(s, 1H, Ph-2-H), 7.29 (dd, J = 9.0 Hz, J′ = 1.5 Hz, 1H, tacrine 7-H), 7.68 (br s, 1H, tacrine 5-H), 7.74 (s, 1H,
triazole 5-H), 7.85 (d, J = 9.0 Hz, 1H, tacrine 8-H); 13C-NMR (75 MHz, DMSO-d6) δ 22.9 (CH2, tacrine
C2), 23.5 (CH2, tacrine C3), 24.8 (CH2, tacrine C4), 25.7 (CH2, tacrine C1), 33.0 (CH2, C2), 33.6 (CH2,
CONHCH2), 44.2 (CH2, NH-CH2-CH2-N), 51.6 (CH2, NH-CH2-CH2-N), 56.4 (CH3, Ph-3-OCH3), 112.4
(CH, Ph-C2), 116.1 (CH, Ph-C5), 117.5 (C, tacrine C8a), 118.8 (C, tacrine C9a), 121.3 (CH, Ph-C6), 124.8
(2CH, triazole C5, tacrine C7), 126.0 (CH, tacrine C8), 126.5 (CH, tacrine C5), 131.1 (C, triazole C4),
133.5 (C, Ph-C1), 136.6 (C, tacrine C6), 146.1 (C, Ph-C4), 146.8 (C, Ph-C3), 148.9 (C, tacrine 10a), 153.6
(C, tacrine C9), 158.8 (C, tacrine C4a), 171.4 (C, C1); MS (ESI+) 521 [M]+; HRMS (ESI+), calculated for
C27H3035ClN6O3 [M + H]+ 521.2068, found 521.2072; HPLC purity 95.9% (tR = 20.6 min, method B).
3.2. Biological Profiling
3.2.1. Evaluation of hAChE and hBChE Inhibitory Activity
The inhibitory activity of the novel compounds on human recombinant AChE and on
human serum BChE (Sigma, Milan, Italy) was evaluated spectrophotometrically by the method
of Ellman et al. [34]. The AChE stock solution was prepared by dissolving human recombinant
AChE lyophilized powder in 0.1% Triton X-100/0.1 M potassium phosphate, pH 8.0. The stock
solution of human serum BChE was prepared by dissolving the lyophilized powder in aqueous 0.1%
gelatine. The stock solutions of the novel compounds (1 mM) were prepared in MeOH. The assay
solution contained 340 µM 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), 0.02 unit/mL hAChE or hBChE,
and 550 µM substrate (acetylthiocholine iodide or butyrylthiocholine iodide, for AChE and BChE,
respectively), in 0.1 M potassium phosphate, pH 8.0. Assay solutions with and without inhibitor were
preincubated at 37 ◦C for 20 min, and then the substrate was added. Blank solutions containing all
components except the enzymes were prepared in parallel to correct for non-enzymatic hydrolysis
of the substrate. Initial rate assays were performed at 37 ◦C with a Jasco V-530 double beam
spectrophotometer. At least five increasing concentrations of the inhibitors, which produced 20–80%
inhibition of the enzymatic activity, were assayed. IC50 values were calculated using Microcal Origin
3.5 software (Microcal Software, Inc., Darmstadt, Germany).
3.2.2. PAMPA-BBB Assay
The brain permeability (Pe) of the target compounds was determined in vitro using the parallel
artificial membrane permeation assay for blood-brain barrier penetration described by Di et al. [41],
employing a lipid extract of porcine brain membrane in a mixture of PBS/EtOH 70:30. Assay
validation was implemented by comparing the experimental and reported Pe values of a set of fourteen
commercial drugs (Table 2). A good correlation was obtained: Pe (exp) = 1.5087 Pe (lit) − 0.8974
(R2 = 0.9296). From this equation, and taking into account the limits established by Di et al. for BBB
permeation, the following ranges of permeability were established: high BBB permeation (CNS+):
Pe (10−6 cm s−1) > 5.13; low BBB permeation (CNS−): Pe (10−6 cm s−1) < 2.12, and uncertain BBB
permeation (CNS±): 5.13 > Pe (10−6 cm s−1) > 2.12.
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Table 2. Experimental and reported BBB permeability (Pe 10−6 cm s−1) values of the commercial drugs
used for assay validation.
Compound Reported Pe 1 Experimental Pe 2
Cimetidine 0.0 0.7 ± 0.1
Lomefloxacin 1.1 0.8 ± 0.1
Norfloxazin 0.1 0.9 ± 0.1
Ofloxazin 0.8 1.0 ± 0.1
Hydrocortisone 1.9 1.4 ± 0.1
Piroxicam 2.5 1.8 ± 0.1
Clonidine 5.3 6.5 ± 0.1
Corticosterone 5.1 6.7 ± 0.1
Imipramine 13.0 12.3 ± 0.1
Promazine 8.8 13.8 ± 0.3
Progesterone 9.3 16.8 ± 0.3
Desipramine 12.0 17.8 ± 0.1
Testosterone 17.0 24.7 ± 1.4
Verapamil 16.0 25.4 ± 1.6
1 Taken from [41]; 2 Values are expressed as the mean ± SD of three independent experiments.
3.3. Structural Biology
3.3.1. Crystallization and Data Collection
TcAChE (12 mg mL−1), purified according to Sussman et al. [48], was crystallized by the
hanging-drop vapor diffusion method. Equal volumes (1 µL) of protein solution and of 30% PEG
200/50 mM MES, pH 6.0, were mixed at 4 ◦C. Crystals appeared within a few days, and were harvested
after 2–3 weeks. The crystals were then soaked in the above-mentioned mother liquor complemented
with the candidate compounds at a concentration of 1 mM, for at least 12 h. All data were collected on
the ID30A1 beamline of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) from
crystals flash-frozen and stored in liquid nitrogen until utilized.
3.3.2. Data Processing and Refinement
Diffraction images were indexed and integrated using XDS, and intensities were further scaled
and merged with XSCALE. Phases were retrieved using the molecular replacement technique with
PHASER. PDB entry 2Xi4 served as the starting model of TcAChE that was employed. All data were
obtained from orthorhombic TcAChE crystals, and two subunits were placed in the asymmetric unit of
all complex structures. The model was refined by iterative cycles of refinement with phenix.refine and
model building using Coot. With phenix.refine, refinement of atomic positions and individual isotropic
temperature factors was performed in real space (against the experimental electron density map)
and in reciprocal space (against experimental intenstities). All ligand topologies were generated
with the PRODRG server and their occupancies were refined during the final cycles of refinement.
The coordinates and structure factors have been deposited in the Protein Data Bank under accession
code 6FOT, 6FOU, and 6FOV, for structures of complexes of 5, 6 and 16, respectively, with TcAChE.
Data collection and refinement statistics are presented in Table 3.
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Table 3. Data collection and refinement statistics. 1
5 6 16
Resolution range (Å) 44.04–1.79 (1.854–1.79) 46.03–1.82 (1.82–1.89) 45.7–1.9(1.968–1.9)
Space group P 21 21 21 P 21 21 21 P 21 21 21
Unit cell (Å) 91.44 106.61 150.53 91.74 106.44 150.68 91.82 106.81 151.67
Total reflections 634,220 (58,489) 642,785 (63,116) 1,072,187 (87,007)
Unique reflections 138,453 (13,737) 130,469 (12,879) 117,742 (11,618)
Multiplicity 4.6 (4.3) 4.9 (4.9) 7.7 (7.5)
Completeness (%) 99.66 (99.75) 98.4 (91.8) 99.71 (99.38)
Mean I/sigma(I) 12.9 (1.5) 12.6 (1.6) 8.8 (1.0)
Wilson B-factor (Å2) 24.63 24.09 29.21
R-merge 0.067 (0.943) 0.075 (1.054) 0.128 (1.286)
CC1/2 0.998 (0.686) 0.999 (0.719) 0.998 (0.588)
Reflections used in refinement 138,303 (13,721) 159,670 (14,805) 117,502 (11,589)
Reflections used for R-free 6854 (681) 7990 (773) 5876 (580)
R-work 0.1797 (0.3422) 0.1896 (0.3100) 0.1880 (0.3357)
R-free 0.2125 (0.3788) 0.2193 (0.3114) 0.2177 (0.3411)
Number of non-hydrogen atoms 9962 9719 9640
macromolecules 8591 8583 8564
ligands 321 153 163
solvent 1040 983 916
Protein residues 1067 1064 1068
RMS (bonds) (Å) 0.006 0.007 0.007
RMS (angles) (◦) 0.88 0.86 0.88
Ramachandran favored (%) 96.29 96.30 96.03
Ramachandran allowed (%) 3.71 3.70 3.88
Ramachandran outliers (%) 0.00 0.00 0.09
Rotamer outliers (%) 0.74 1.40 2.40
Clashscore 4.19 3.67 3.45
Average B-factor (Å2) 31.03 31.94 35.77
macromolecules 29.49 30.88 34.72
ligands 45.26 45.93 50.66
solvent 39.32 38.98 42.98
1 Statistics for the highest-resolution shell are shown in parentheses.
4. Conclusions
Starting from the chemical structures of the potent brain-permeable AChE inhibitors tacrine,
6-chlorotacrine, and huprine Y, which are of interest in the context of Alzheimer’s disease treatment,
we have designed and synthesized two series of derivatives of increased polarity with the aim of
precluding their penetration into the central nervous system, thus confining their anticholinesterase
action to the peripheral level for potential therapeutic use against myasthenia gravis. In one of
the series, we increased polarity by the classic approach based on quaternization by alkylation of a
nucleophilic nitrogen atom, which produced the quinolinium derivatives of tacrine, 6-chlorotacrine,
and huprine Y 4–6. In a second series, we increased polarity by installation of a 1,2,3-triazole ring
within a side chain at position 9 of tacrine and 6-chlorotacrine (compounds 9 and 10), and of an
additional polyphenol-like moiety in compounds 15 and 16. In general, these structural changes
lead to decreased AChE and BChE inhibitory activities relative to the parent compounds, with the
exception of the triazole-containing compound 16, which is a more potent AChE and BChE inhibitor
than the parent 6-chlorotacrine, likely as a result of multi-site binding within the active-site gorge of
the enzyme, as confirmed by the crystal structure of its complex with TcAChE. Despite their lower
anticholinesterase potencies compared with the parent compounds, most of the novel derivatives are
clearly more potent than pyridostigmine, the preferred drug for symptomatic treatment of myasthenia
gravis, and have been found to display low brain permeability values in the PAMPA-BBB assay, thus
possessing favorable pharmacodynamic and pharmacokinetic attributes for the intended use against
myasthenia gravis.
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